Quantinno Capital Management LP Boosts Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Quantinno Capital Management LP grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 54.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,991 shares of the medical equipment provider's stock after purchasing an additional 8,114 shares during the period. Quantinno Capital Management LP's holdings in Intuitive Surgical were worth $11,295,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Hazlett Burt & Watson Inc. grew its stake in Intuitive Surgical by 5.8% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider's stock worth $177,000 after purchasing an additional 20 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. boosted its stake in shares of Intuitive Surgical by 4.1% in the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider's stock valued at $247,000 after buying an additional 20 shares during the period. Ullmann Wealth Partners Group LLC grew its position in shares of Intuitive Surgical by 1.6% during the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider's stock worth $653,000 after buying an additional 21 shares in the last quarter. Meeder Advisory Services Inc. increased its stake in shares of Intuitive Surgical by 0.3% during the third quarter. Meeder Advisory Services Inc. now owns 7,386 shares of the medical equipment provider's stock worth $3,629,000 after buying an additional 22 shares during the period. Finally, One Wealth Management Investment & Advisory Services LLC raised its holdings in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider's stock valued at $310,000 after acquiring an additional 23 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Buying and Selling at Intuitive Surgical

In related news, CEO Gary S. Guthart sold 18,151 shares of the company's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the transaction, the chief executive officer now owns 24,219 shares of the company's stock, valued at $12,391,166.97. This represents a 42.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Gary Loeb sold 300 shares of the firm's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $475.00, for a total value of $142,500.00. Following the completion of the sale, the general counsel now directly owns 1,595 shares of the company's stock, valued at approximately $757,625. This trade represents a 15.83 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,023 shares of company stock valued at $26,384,247. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Trading Up 0.5 %

Shares of NASDAQ ISRG traded up $2.76 during midday trading on Friday, reaching $550.41. 1,026,203 shares of the company were exchanged, compared to its average volume of 1,445,625. The stock has a fifty day simple moving average of $514.78 and a 200 day simple moving average of $472.60. The stock has a market cap of $196.04 billion, a P/E ratio of 88.49, a PEG ratio of 5.33 and a beta of 1.38. Intuitive Surgical, Inc. has a 1 year low of $307.72 and a 1 year high of $556.23.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. As a group, analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ISRG. Morgan Stanley raised shares of Intuitive Surgical from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $522.00 to $650.00 in a research report on Monday. Erste Group Bank upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Tuesday, November 19th. BTIG Research raised their price target on Intuitive Surgical from $535.00 to $561.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Oppenheimer reaffirmed a "market perform" rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Raymond James increased their price objective on Intuitive Surgical from $500.00 to $540.00 and gave the company an "outperform" rating in a report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and a consensus price target of $541.33.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.